The first NETRF/ERF Nuclear Medicine Pilot Research Grant has been awarded to Thomas Hope, MD. NETRF is funding the grant to explore innovations in nuclear medicine focused on diagnosis and treatment. ERF—The Education and Research Foundation for Nuclear Medicine and Molecular Imaging—solicited proposals and convened the scientific review panel to select the grantee. Dr. Hope’s project is “Intra-Arterial Peptide Receptor Radionuclide Therapy (I-A PRRT) using 90Y DOTA-TOC.” The primary goals are to evaluate possible liver, bone marrow and kidney toxicity after hepatic arterial injection and evaluate imaging tumor response to 90Y-DOTA-TOC hepatic arterial injection three months after treatment. Dr. Hope’s co-principle investigators are Emily Bergsland, MD, and Nicholas Fidelman, MD.